RPT-UPDATE 2-Express Scripts drops Gilead hep C drugs for cheaper AbbVie rival

Dec 22 (Reuters) - The largest U.S. pharmacy benefit manager said on Monday it has lined up a cheaper price for AbbVie Inc's newly approved hepatitis C treatment and, in most cases, will no longer cover Gilead Sciences Inc's treatments after trying for nearly a year to win a deeper discount.